|Articles|May 6, 2020
Advanced Analytical Workflow Solutions for Monitoring Critical Quality Attributes of Monoclonal Antibodies
Recombinant mAbs tend to be unstable and susceptible to modification/degradation. These mAbs need to be identified/monitored for successful drug development. New advanced LC–MS workflows have been developed to meet such needs.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5